Yesterday, the main bio-pharmaceutical Changchun High-tech announcement, said recently, pharmaceutical companies under the holding company Changchun, one hundred grams Pharmaceutical Co., Ltd. (hereinafter referred to as "one hundred grams medicine") to declare the treatment of type AIDS vaccine project has been formally received State Food and Drug Administration issued a "Clinical Trial Approval," approved to enter Phase I clinical trials, the admissibility number CXSB0900024.

It is reported that the project is by the Chinese Centre for Disease Control and Prevention borne viral disease prevention and control development, and in 2008 as a national major science and technology issues, "China AIDS patients immune therapy (subject number: 2008ZX10001-009) to obtain approval of the Ministry of Science implementation. June 2009, one hundred grams Pharmaceutical and virus prevention and control of the sign "special projects of major national science and technology (the subject) cooperation agreement" to jointly develop the project, according to the agreement states: The issue of intellectual property obtained prior to the beginning ownership of all the original units, obtained through the issue of intellectual property rights, ownership of units subordinate units independently, is a collaboration by the two sides shared.

Changchun High-tech said, I clinical trial primary endpoint is a preliminary study carried out HARRT the vaccine after treatment of HIV-1 infection of safety, success, there are still significant uncertainties. Even if the Phase I clinical trial is successful, the vaccine also needs to II, III clinical trials. Therefore, clinical trials, each of the project development process each takes a long time and there are clinical trials, the risk of failure. And given the treatment of type AIDS vaccine clinical trials is a long-term research and investment process that can not be allowed to produce market in the short term, please pay attention to investment risks investors.

However, it is worth noting that, who is also the "new three-panel" and "anti-AIDS" concept of the Changchun High-tech, recent performance in the secondary market is very active. To media reports, this years "new three board" Zhongguancun Science Park will be in the original pilot basis to high-tech park to promote the country, is expected in the "two sessions" after the formal announcement of the expansion program, the park will benefit 15 to 20.

The data from the National Science and Technology website, the current total of 83 national high-tech industrial development zones, the parks high-tech enterprises are the "new three-panel" alternative "stock pools", and listed the park as a high-tech companies Changchun High-tech affected, the stock has an upward trend. From inception on January 26, the stock rose steadily to 61.88 yuan / share, an increase of 19.3%.